IP Library Granted Patent US 10,130,600
Granted Patent B2
US 10,130,600 · App. 14/890,106 · Granted Nov 20, 2018

Lipid scavenging in Ras cancers

Inventors: Joshua Rabinowitz (Princeton, NJ); Jurre Kamphorst (Glasgow, GB); Craig Thompson (New York, NY); Justin Cross (New York, NY)
Assignees: Memorial Sloan Kettering Cancer Center; The Trustees of Princeton University
A61K31/20A23L33/10A23L33/115A23L33/12A23L33/17A61K31/202A61K45/06G01N33/5748A23V2002/00A61K31/66A61K31/685A61K36/889G01N2500/10G01N2800/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,130,600
App. No.
14/890,106
Granted
Nov 20, 2018
Kind
B2
Abstract

Methods and compositions for treating Ras-related cancers are provided that involve targeting lipid scavenging. Methods and compositions for identifying and/or characterizing more or less responsive cancers are also provided.

Claims (14)

1. A method of identifying and/or characterizing an agent useful for the treatment of a Ras-driven cancer and/or a hypoxic tumor by determining its effect on lipid scavenging as compared with an appropriate control, wherein the step of determining comprises

contacting a population of tumor cells with at least one test agent;

incubating the cells in the presence of a medium comprising serum, labelled glucose, and labelled glutamine;

measuring amount of labelled fatty acid in the tumor cells;

measuring amount of unlabelled fatty acid in the tumor cells; and

identifying and/or characterizing the at least one test agent for its ability to alter cellular uptake of fatty acids relative to uptake by an otherwise identical cell or tissue that is not cancerous.

2. The method of claim 1 , wherein the cells are immortalized Baby Mouse Kidney (iBMK) cells.

3. The method of claim 1 , wherein the lipid is polyunsaturated.

4. The method of claim 1 , wherein the lipid is a phospholipid.

5. The method of claim 1 , wherein the lipid is a lysophospholipid.

6. The method of claim 1 , wherein the labelled fatty acid comprises 13 C.

7. The method of claim 1 , wherein the labelled fatty acid is labelled by metabolism of U- 13 C-glucose and/or U- 13 C-glutamine.

8. The method of claim 1 , wherein the tumor cells are incubated in a medium having an O 2 level of 1% or less.

9. The method of claim 1 , wherein the tumor cells are incubated in a medium having an O 2 level of 0.5% or less.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 15, 2018
From: RABINOWITZ, JOSHUA; KAMPHORST, JURRE
To: THE TRUSTEES OF PRINCETON UNIVERSITY
Reel/Frame 044947/0252 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 15, 2018
From: THOMPSON, CRAIG; CROSS, JUSTIN
To: MEMORIAL SLOAN KETTERING CANCER CENTER
Reel/Frame 044947/0272 →
CONFIRMATORY LICENSE Recorded Jun 22, 2016
From: SLOAN-KETTERING INST CAN RESEARCH
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 039113/0429 →
Continuity (2)
Provisional Application 61822095 · May 10, 2013
Related Publication 20160120832A1 · May 5, 2016
Cited By (1)
US 12,653,836